



Tarceva® (erlotinib) – Updated Indication

- On October 18, 2016, the [FDA approved Tarceva \(erlotinib\)](#) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen.
 - Safety and efficacy of Tarceva have not been established in patients with NSCLC whose tumors have other EGFR mutations.
 - Tarceva is not recommended for use in combination with platinum-based chemotherapy.
- Previously, Tarceva was approved for:
 - First-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
 - Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
 - The treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
- Tarceva is also approved for use in combination with [gemcitabine](#) for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
- The recommended dose of Tarceva for NSCLC is 150 mg orally on an empty stomach. Treatment should continue until disease progression or unacceptable toxicity occurs.
 - The recommended dose of Tarceva for pancreatic cancer is 100 mg orally once daily in combination with gemcitabine. Consult the gemcitabine package label for recommended dose.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.